Antisense modulation of PKA regulatory subunit RII beta expression
AssigneeIsis Pharmaceuticals, Inc.
InventorsBrett P. Monia, Jacqueline Wyatt
Life of this patent
Estimating the term…
Abstract
Antisense compounds, compositions and methods are provided for modulating the expression of PKA regulatory subunit RII beta. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PKA regulatory subunit RII beta. Methods of using these compounds for modulation of PKA regulatory subunit RII beta expression and for treatment of diseases associated with expression of PKA regulatory subunit RII beta are provided.
Claims20
A compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding PKA regulatory subunit RII beta, wherein said compound specifically hybridizes with said nucleic acid molecule encoding PKA regulatory subunit RII beta and inhibits the expression of PKA regulatory subunit RII beta.
A compound 8 to 50 nucleobases in length which specifically hybridizes with at least an 8-nucleobase portion of an active site on a nucleic acid molecule encoding PKA regulatory subunit RII beta.
Dependencies are inferred from the claim text.